It is currently trading at $6.25 a tad under the 50 day moving average which is $6.67 and a tad below the 200 day moving average of $6.42. The 50 day moving average went down $-0.42 or -6.34% whereas the 200 day moving average was down $-0.17 or -2.62%. Cyclacel Pharmaceuticals, Inc. shares had a trading volume of 830 by the end of trading on Tuesday. Overall, volume was up 15.12% over the stocks normal daily volume.
Short traders are more bullish on shares of the company of late as indicated by the downtick in short interest. The company realized a fall in short interest between September 29, 2017 and October 13, 2017 of -19.80%. Short interest fell 360 over that period. With short interest at 1,458 and short average daily volume at 888, the short-interest ratio is 2.0 and the percentage of shorted shares is 0.00% as of October 13.
A few notable investment firms have updated their holdings. As of quarter end Ubs Group Ag had disposed of 1,356 shares trimming its position 69.0%. The value of the investment in CYCCP decreased from $12,000 to $4,000 a change of 66.7% since the last quarter. As of the end of the quarter Tower Research Capital LLC (trc) had sold a total of 381 shares trimming its holdings by 90.1%. The value of the investment in (CYCCP) went from $3,000 to $0 a change of $3,000 for the reporting period.
The company is so far trading unchanged by % since yesterday’s close of $6.25. Cyclacel Pharmaceuticals, Inc. announced a dividend for shareholders which was paid on Wednesday November 1st, 2017. The dividend was $0.150 per share for the quarter which comes to $0.60 on an annualized basis. This dividend represents a yield of $8.78. The ex-dividend date was set for Thursday the 12th of October 2017.
Cyclacel Pharmaceuticals, Inc., launched on January 5, 1996, operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Business’s family of anticancer drugs acts on the cell cycle..